Scribe Therapeutics, Inc.
SCTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001853921
In the last 90 days, Scribe Therapeutics, Inc. insiders filed 5 open-market purchases and 0 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $56.3M in total
- 5
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026
- 0
- 13F valueReported value at the end of Q2 2026
- $0
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding SCTX, Q2 2026
No superinvestor reported holding SCTX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Scribe Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 29, 2026 (view filing)7:09 PM ET | Jul 27 | 2 days | Andreessen Marc L and 5 others10% Owner | PPurchase | +333.3K | $15.00 | +$5.00M | +16.2%2.39M after | |
| Jul 29, 2026 (view filing)6:50 PM ET | Jul 27 | 2 days | Gordon Carl LDirector | PPurchase | +1.00M | $15.00 | +$15.0M | +286.7%1.35M after | Duplicate filing |
| Jul 29, 2026 (view filing)6:47 PM ET | Jul 27 | 2 days | OrbiMed Advisors LLC and 1 otherDirector | PPurchase | +1.00M | $15.00 | +$15.0M | +286.7%1.35M after | |
| Jul 28, 2026 (view filing)9:30 PM ET | Jul 24-28 | 4 days | Avoro Capital Advisors LLC and 2 othersDirector, 10% Owner, Other: See Remarks | PPurchaseCommon Stock, par value $0.0001 per share | +2.39M | $15.16 | +$36.3M | +342.8%3.09M after | 3 lots |
| Jul 27, 2026 (view filing)9:42 PM ET | Jul 23 | 4 days | Lucas SvetlanaChief Business Officer | PPurchase | +3.00K | $15.00 | +$45.0K | New position3.00K after | |
| Jul 27, 2026 (view filing)9:20 PM ET | Jul 23 | 4 days | Parrot DavidChief Financial Officer | PPurchase | +2.67K | $15.00 | +$40.0K | New position1.33K after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Scribe Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
No institution reported holding SCTX in 13F filings for Q2 2026.